Categories
Uncategorized

Phentermine-topiramate (Qsymia)

Phentermine-topiramate sold as Qsymia is the combination  of an anorexant and an anti-seizure medication.

This combination of agents is associated with an 8% greater weight loss than placebo among adults with obesity.

Phentermine-topiramate associated with reduced weight circumference by approximately 11 cm, decreases systolic blood pressure by 3 mmHg and reduced  low density lipoprotein cholesterol by approximately 6% among adults with obesity.

In patients  with type two diabetes, the combination of drugs achieved in mean weight loss of 9.4% and the hemoglobin A1c reduction of 1.6% at 12 months compared with placebo.

Long term phentermine-topiramate can achieve and sustain a 10% weight reduction.

Common adverse events associated with phentetemine – topiramate include 14 to 20% paresthesia, 14 and 19% dry mouth, 15 to 16% constipation and 7 to 9% dysguesia.

Topiramate is associated with the increased congenital fetal oral cleft malformations, and is contraindicated during pregnancy.

 

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *